Complexa, Inc., a Pittsburgh, PA-based biopharmaceutical company focused on treating inflammatory and metabolic disorders with nitrated unsaturated fatty acids, raised $200k in funding.
Founded in 2008, Complexa initially focuses on acute and chronic kidney disease. Its lead compound (CXA-10) is targeted for the treatment of contrast imaging (dye)-induced nephropathy (CIN) a form of acute kidney injury (AKI) that can lead to extended hospitalization, dialysis or death.
Its pipeline also includes several proprietary second generation drug candidates which are structurally distinct from CXA-10 and are being developed to target a significant inflammatory and metabolic conditions and facilitate future partnering opportunities.
The company is led by:
– Joshua M. Tarnoff – Director, President and Chief Executive Officer
– Diane Jorkasky, MD, FACP – Chief Scientific Officer, and
– Steven M. Plumb, CPA – Chief Financial Officer.